Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Elena Shagisultanova"'
Autor:
Anthony D. Elias, Alyse W. Staley, Monica Fornier, Gregory A. Vidal, Vida Alami, Sharon Sams, Nicole S. Spoelstra, Andrew Goodspeed, Peter Kabos, Jennifer R. Diamond, Elena Shagisultanova, Rosa I. Gallagher, Julia D. Wulfkuhle, Emanuel F. Petricoin, Kathryn L. Zolman, Tessa McSpadden, Kimberly R. Jordan, Jill E. Slansky, Virginia F. Borges, Dexiang Gao, Jennifer K. Richer
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-14 (2024)
Abstract Most ER+ breast cancers (BC) express androgen receptors (AR). This randomized phase II trial of 4 months of neoadjuvant fulvestrant (Fulv) alone or with enzalutamide (Combo) assessed whether adding AR blockade to Fulv would limit residual tu
Externí odkaz:
https://doaj.org/article/564ac0eba47340f495698648097af1b7
Autor:
Anthony D. Elias, Nicole S. Spoelstra, Alyse W. Staley, Sharon Sams, Lyndsey S. Crump, Gregory A. Vidal, Virginia F. Borges, Peter Kabos, Jennifer R. Diamond, Elena Shagisultanova, Anosheh Afghahi, Jose Mayordomo, Tessa McSpadden, Gloria Crawford, Angelo D’Alessandro, Kathryn L. Zolman, Adrie van Bokhoven, Yonghua Zhuang, Rosa I. Gallagher, Julia D. Wulfkuhle, Emanuel F. Petricoin III, Dexiang Gao, Jennifer K. Richer
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-10 (2023)
Abstract This clinical trial combined fulvestrant with the anti-androgen enzalutamide in women with metastatic ER+/HER2− breast cancer (BC). Eligible patients were women with ECOG 0–2, ER+/HER2− measurable or evaluable metastatic BC. Prior fulv
Externí odkaz:
https://doaj.org/article/ad0c82b5d82a4e81a6170a0a923d1435
Autor:
Allison H. West, Hayley Knollman, James Dugan, Donald Hedeker, Elisabeth A. Handorf, Sarah M. Nielsen, Lisa C. Bealin, Lindsay G. Goldblatt, Heather Willems, Mary B. Daly, Anosheh Afghahi, Olufunmilayo I. Olopade, Peter J. Hulick, Elena Shagisultanova, Dezheng Huo, Elias Obeid, Jane E. Churpek
Publikováno v:
Cancer Medicine, Vol 8, Iss 12, Pp 5609-5618 (2019)
Abstract Women who inherit a BRCA1 or BRCA2 mutation have an increased risk of breast cancer. Preliminary evidence suggests they may also have defects in bone marrow function. To test this hypothesis, we conducted a multicenter, retrospective, matche
Externí odkaz:
https://doaj.org/article/d695927560f54771808c59d4bbf454a7
Publikováno v:
International Journal of Breast Cancer, Vol 2018 (2018)
Triple positive breast cancers overexpress both the human epidermal growth factor receptor 2 (HER2) oncogene and the hormonal receptors (HR) to estrogen and progesterone. These cancers represent a unique therapeutic challenge because of a bidirection
Externí odkaz:
https://doaj.org/article/2887162eaf5b4c3999d19a13c739b2cd
Autor:
Elena Shagisultanova, Kari B. Wisinski, Chelsea D. Gawryletz, Farrah M. Datko, Diana Medgyesy, Jennifer R. Diamond, Virginia F. Borges, Peter Kabos
Publikováno v:
Cancer Research. 83:OT3-09
Phosphatidylinositol 3-kinase (PI3K) pathway plays a key role in resistance to the drugs targeting human epidermal growth factor receptor 2 (HER2). Activating mutations in the gene encoding alpha catalytic subunit of PI3K (PIK3CA) are present in appr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::805b91032953767b61432226556e55ee
https://doi.org/10.1158/1538-7445.sabcs22-ot3-09-01
https://doi.org/10.1158/1538-7445.sabcs22-ot3-09-01
Autor:
Elena Shagisultanova, Dexiang Gao, Eryn Callihan, Hannah J. Parris, Betsy Risendal, Lisa M. Hines, Martha L. Slattery, Kathy Baumgartner, Pepper Schedin, Esther M. John, Virginia F. Borges
Publikováno v:
Eur J Cancer
BACKGROUND: Women diagnosed with breast cancer prior to age 45 years (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5af40bb8f70202eaaeaa93ed7589df88
https://doi.org/10.1016/j.ejca.2022.03.014
https://doi.org/10.1016/j.ejca.2022.03.014
Autor:
Nicholas Turner, Christos Vaklavas, Emiliano Calvo, Javier Garcia-Corbacho, Jason Incorvati, Manuel Ruiz Borrego, Chris Twelves, Anne Armstrong, Begoña Bermejo, Erika Hamilton, Mafalda Oliveira, Eva Ciruelos, Peter Kabos, Manish R Patel, Maria Borrell, Howard Burris, Bruno de Paula, Alejandro Falcon, Cristina Hernando, Irene Moreno, Ciara S. O’Brien, Elena Shagisultanova, Ivan Victoria Ruiz, Judy S. Wang, Mei Wei, Tim Brier, Danielle Carroll, Carmela Ciardullo, Lisa Gibbons, itziar irurzun-Arana, Tony Jack, bistra kirova, Teresa Klinowska, Justin Lindemann, Julie Maidment, Alastair Mathewson, Rhiannon Maudsley, Robert McEwen, Christopher Morrow, Andy Sykes, Richard D. Baird
Background: SERENA-1 (NCT03616587) is a Phase 1, multi-part, open-label study of camizestrant in women with ER+/HER2− advanced breast cancer. Parts A/B and C/D (escalation/expansion) examined camizestrant as monotherapy and in combination with palb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff3b0f1e0fcbdd82a029a528d47540d2
https://www.repository.cam.ac.uk/handle/1810/350214
https://www.repository.cam.ac.uk/handle/1810/350214
Autor:
Elena Shagisultanova, William Gradishar, Ursa Brown-Glaberman, Pavani Chalasani, Andrew Brenner, Alison Stopeck, Jose Mayordomo, Jennifer Diamond, Peter Kabos, Virginia F. Borges
Publikováno v:
Cancer Research. 82:P1-18
Background: The phase IB/II clinical trial of tucatinib, palbociclib and letrozole (NCT03054363) showed activity in heavily pretreated patients (pts) with HR+/HER2+ metastatic breast cancer (Shagisultanova et. al, Cancer Res 2021:81(4), PS10-03). Her
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::21d82fe75875a4d0dbb7ae31807ec144
https://doi.org/10.1158/1538-7445.sabcs21-p1-18-26
https://doi.org/10.1158/1538-7445.sabcs21-p1-18-26
Autor:
Jennifer Richer, Nicole Spoelstra, Alyse Winchester, Julia Wulfkuhlue, Rosa Gallagher, Sharon Sams, Gregory Vidal, Peter Kabos, Jennifer Diamond, Elena Shagisultanova, Anosheh Afghahi, Jose Mayordomo, Tessa McSpadded, Gloria Crawford, Virginia Borges, Dexiang Gao, Emanuel Petricoin, Anthony Elias
Publikováno v:
Cancer Research. 82:P1-17
Background: The clinical implications of the androgen receptor (AR), particularly in the context of aromatase inhibitor (AI) refractory metastatic breast cancer (MBC), are unclear. While AR is associated with more indolent primary tumors, in the abse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::abe63f468ac7349b194565e8752303fd
https://doi.org/10.1158/1538-7445.sabcs21-p1-17-01
https://doi.org/10.1158/1538-7445.sabcs21-p1-17-01
Autor:
Lyndsey S. Crump, Traci R. Lyons, Elena Shagisultanova, Peter Kabos, Virginia F. Borges, Aryana R Rasti, Michelle Borakove, Benjamin A Harrison, Jessica K. Hall
Publikováno v:
Mol Cancer Ther
Breast cancers that express hormonal receptors (HR) and HER2 display resistance to targeted therapy. Tumor-promotional signaling from the HER2 and estrogen receptor (ER) pathways converges at the cyclin D1 and cyclin-dependent kinases (CDK) 4 and 6 c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9addc567d5e2ed9d8ad60c3ca625a96d
https://doi.org/10.1158/1535-7163.mct-21-0098
https://doi.org/10.1158/1535-7163.mct-21-0098